Profil
Tsvetelina Pencheva Hoang formerly worked at Bellicum Pharmaceuticals, Inc., as Director-Translational Research from 2015 to 2018, The Phi Beta Kappa Society, as Member, and Marker Therapeutics, Inc., as Vice President-Research & Development from 2018 to 2024.
Dr. Hoang received her doctorate degree from The Johns Hopkins University and undergraduate degree and graduate degree from Yale University.
Ehemalige bekannte Positionen von Tsvetelina Hoang
| Unternehmen | Position | Ende |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2024 |
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2018 |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services Operates as a organisation for liberal arts and science education | Corporate Officer/Principal | - |
Ausbildung von Tsvetelina Hoang
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services Operates as a organisation for liberal arts and science education | Commercial Services |
















